Could Protagonist Therapeutics Inc. (NASDAQ:PTGX) cool soon?

1067

Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) last traded at $11.82. The company’s performance year to date is -46.25%. The 200 day simple moving average is -28.35%. The 200 simple moving average (SMA) is considered a key indicator by traders and market analysts for determining the overall long-term trend. The price level in a market that coincides with the 200 SMA is recognized as a major support when price is above the 200 SMA or resistance when price is below the 200 SMA level.

As per recent filings, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has an insider ownership of 1.10%.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has been storming Wallstreet with solid press release. Recently, the company announced that according to the March 2017 study commissioned by RetailMeNot and conducted by Forrester Consulting, the company’s mobile marketing solutions generate a three-year, risk-adjusted return on investment (ROI) of 4.3x.

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Weak.

The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oil prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). The long term and short term EMA’s of 9.95 and 11.21 are lower than the current trading price suggesting a bullish pattern in both short term as well as long term. .

The relative strength index (RSI) is a momentum oscillator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). The current RSI is 59.68 suggesting a bullish price action.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is all set to announce its earnings on Mar 01. As per Zack’s analyst ratings, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) currently has an average brokerage rating of 1. On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:PTGX) is $23.5 with a high of $29 and a low of $18.

As such, while we believe Protagonist Therapeutics, Inc. (NASDAQ:PTGX) represents a compelling growth story exposed to several secularly attractive markets, it would be interesting to see how it fairs for long-term investors.

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the company has initiated a Phase 1 clinical study of PTG-300 in normal healthy volunteers. PTG-300 is an injectable hepcidin mimetic peptide discovered using the company’s proprietary technology platform, and it is being developed as a potential treatment for patients with chronic iron overload in rare diseases such as beta-thalassemia.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.